Radioactive antibody targets Hard-to-Treat cancers in early trial
NCT ID NCT07189871
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and aims to find the safest dose and see if the drug can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER (CRPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BAMF Health
RECRUITINGGrand Rapids, Michigan, 49503, United States
-
Dothan Hematology & Oncology
RECRUITINGDothan, Alabama, 36303, United States
-
Nebraska Cancer Specialists
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
XCancer
RECRUITINGOmaha, Nebraska, 68130, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a smart digital program restore sleep for cancer survivors?